Nightstar becomes nightmare, but Biogen has bigger fish to fry

It is just as well that Aduhelm was approved, adding $18bn to Biogen’s market cap, otherwise the group’s business development decisions would now be coming under fire. Yesterday’s failure of the second of two gene therapies Biogen got from Nightstar has rendered that $877m acquisition, done in 2019, worthless.